Drug Approval | May 07, 2024
Alembic Pharmaceuticals receives EIR from USFDA for oncology formulation facility
With this, for all our USFDA facilities, EIRs are in place
With this, for all our USFDA facilities, EIRs are in place
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Both organisations enter into a long- term collaboration to expand patient access in India
The company will provide comprehensive response to USFDA for the observations
Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
High-quality baobab oil sourced in collaboration with UNCCD and the Great Green Wall Initiative
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
Total transaction value of the divestment is Rs. 3,660 million
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Subscribe To Our Newsletter & Stay Updated
